Ionis Pharmaceuticals, Inc. Common Stock (IONS) — Analysis Summary
Ionis Pharmaceuticals, Inc. Common Stock (IONS) has a market cap of $10.37B with year-over-year revenue growth of +33.8%. Net margin stands at -40.4%. The stock trades at a P/E ratio of -18.4.
Key Takeaways
- Revenue changed +33.8% year-over-year
- Net margin of -40.4%
- P/E ratio of -18.4
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, IONS posted revenue growth of +33.8% and trades at a P/E of -18.4.
Ionis Pharmaceuticals, Inc. Common Stock (IONS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -31.6x — earnings do not cover interest payments
Operating margin at -68.0% — severe operating losses
Net margin at -64.7% — significant losses
Net income fell 48.2% vs the prior period.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Sector
PHARMACEUTICAL PREPARATIONS
Employees
1,402
Headquarters
CARLSBAD, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.